Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29147
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMontalban, X.-
dc.contributor.authorBarone, D.-
dc.contributor.authorBroadley, S.-
dc.contributor.authorDive, D.-
dc.contributor.authorHupperts, R. M.-
dc.contributor.authorLycke, J.-
dc.contributor.authorMassacesi, L.-
dc.contributor.authorNaismith, R. T.-
dc.contributor.authorNakamura, K.-
dc.contributor.authorPandey, K.-
dc.contributor.authorSchippling, S.-
dc.contributor.authorVermersch, P.-
dc.contributor.authorWiendl, H.-
dc.contributor.authorChung, L.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorAfsar, S.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.date.accessioned2019-09-10T14:08:57Z-
dc.date.available2019-09-10T14:08:57Z-
dc.date.issued2019-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 26, p. 678-678-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/29147-
dc.description.sponsorshipSTUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.-
dc.language.isoen-
dc.publisherWILEY-
dc.titleAlemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 29-JUL 02, 2019-
local.bibliographicCitation.conferencename5th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceOslo, NORWAY-
dc.identifier.epage678-
dc.identifier.spage678-
dc.identifier.volume26-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Montalban, X.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Barone, D.] Rowan Univ, Glassboro, NJ USA. [Broadley, S.] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia. [Dive, D.] Univ Hosp Ctr Liege, Liege, Belgium. [Hupperts, R. M.] Maastricht Univ, Med Ctr, Orbis Med Ctr, Sittard, Netherlands. [Lycke, J.] Univ Gothenburg, Gothenburg, Sweden. [Massacesi, L.] Univ Florence, Florence, Italy. [Naismith, R. T.] Washington Univ, Sch Med, St Louis, MO USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [Pandey, K.] Hackensack Univ Hosp, Multiple Sclerosis Care Ctr, Hackensack, NJ USA. [Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Vermersch, P.] Univ Lille, Lille, France. [Wiendl, H.] Univ Munster, Munster, Germany. [Chung, L.; Daizadeh, N.; Afsar, S.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000474481003051-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.fullcitationMontalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S. & VAN WIJMEERSCH, Bart (2019) Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study). In: EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 678-678.-
item.contributorMontalban, X.-
item.contributorBarone, D.-
item.contributorBroadley, S.-
item.contributorDive, D.-
item.contributorHupperts, R. M.-
item.contributorLycke, J.-
item.contributorMassacesi, L.-
item.contributorNaismith, R. T.-
item.contributorNakamura, K.-
item.contributorPandey, K.-
item.contributorSchippling, S.-
item.contributorVermersch, P.-
item.contributorWiendl, H.-
item.contributorChung, L.-
item.contributorDaizadeh, N.-
item.contributorAfsar, S.-
item.contributorVAN WIJMEERSCH, Bart-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Show simple item record

Page view(s)

34
checked on Jul 28, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.